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Poster Session II S307Conclusions: Progressive improvement in cutaneous manifestations
of cGVHD was observed following a 24-week course of ECP in pts
who previously had exhibited no clinical response or worsening of
cGVHD while receiving standard immunosuppressive therapy
with corticosteroids. ECP improved skin GVHD and allowed for ta-
pering of corticosteroid doses to ‘‘low risk’’ levels of\10 mg predni-
sone-equivalents/day.406
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Donor T cell alloreactivity can be co-opted to deliver a graft-versus-
tumor (GVT) response following blood or bone marrow transplanta-
tion (BMT). However, the major reason for treatment failure
following BMT is tumor recurrence, suggesting a long-term failure
of GVT immunity. In this study, we have considered the role of
non-hematopoietic antigen in determining the fate of donor CD8 cells
in a model of delayed DLI to partially MHC-mismatched chimeras,
where antigen was either expressed ubiquitously or restricted to the
hematopoietic compartment. We observed that donor CD8 cytotoxic
and cytokine responses were poorly sustained (at .8 weeks) in the
presence of non-hematopoietic antigen and this was associated with
a failure to establish a central memory (TCM) population. This effect
occurred at two distinct levels. Firstly, residual donor CD8 cells dem-
onstrated a classic PD-1highCD127low ‘exhaustion’ signature and con-
sistent with this, CD8 functions were partially restored by blockade of
the PD-1 pathway. Secondly, during the initial phase of the primary
response (at day 5-8 following transfer of CFSE-labelled splenocytes),
we observed that the proportion of post-mitotic, CFSElow CD8 cells
expressing a CD44highCD62Lhigh phenotype was much lower in chi-
meras where antigen was ubiquitous. These findings suggested the
possibility that early CD8 encounter with non-hematopoietic antigen
might severely disable memory precursor formation during the initial
phase of the response. In order to test this concept, we purified CD8 T
cells using congenic markers from the two sets of chimeras 14 days af-
ter initial T cell transfer, and then parked them in secondary, antigen
free hosts. After 21 days, we tested recall responses to alloantigen. We
found that priming in the presence of non-hematopoietic antigen se-
verely impaired the establishment of recall immunity in the absence of
antigen. Furthermore, while a significant proportion of CD8 T cells
primed in the absence of non-hematopoietic antigen had a (TCM) phe-
notype in secondary hosts, this population was almost entirely absent
when initial priming occurred in primary hosts where antigen was
ubiquitous. These data demonstrate that alloantigen within non-he-
matopoietic tissues is not ignored, but rather actively inhibits both
the formation and maintenance of CD8 T cell memory. While these
effects may lessen the risk of GVHD, they might also impair the dura-
bility of the GVT response.407
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Thymic GVHD (tGVHD) is associated with prolonged immuno-
deficiency. We previously found that thymic output after allo-BMT
is directly related to thymus size, and inversely related to donor T
cell dose and GVHD severity. Additionally, radiation-containing
preparative regimens upregulate the death receptors Fas and DR5
on thymic stroma and decrease expression of cFLIP, thus sensitizing
the thymus to GVHD. Finally, very few donor alloreactive T cellsare sufficient to cause tGVHD via the Fas/Fas ligand (FasL) and
TRAIL/DR5 pathways.
Here, we performed allo-BMT in MHC-mismatched and
MHC-matched minor antigen-disparate model systems, and dem-
onstrated the exquisite sensitivity of the thymus to as few as
1-2.5105 donor T cells, which mediated tGVHD without sig-
nificant clinical GVHD. Additionally, tGVHD is partially revers-
ible in our models (contingent on low T cell dose), such that
mice with tGVHD exhibit a partial recovery in thymic cellularity
late (day 60) post-transplant.
We further studied the role of TRAIL in tGVHD, by asking
whether alloreactive T cells and GVHD or conditioning-associated
inflammation were strictly required for TRAIL/DR5-mediated
damage. We treated recipients of T cell-depleted allo-BMT with
mDR5-1 agonistic antibody either in the ‘‘early’’ peri-transplant pe-
riod, or ‘‘late,’’ in the second week post-transplant.
Allo-BMT recipients treated ‘‘early’’ with mDR5-1 had signifi-
cantly decreased thymic cellularity and splenic BM-derived T cells
as compared with controls. Furthermore, we observed similar BM cel-
lularity and BM-derived lineage- sca-1+ckit+ (LSK), all in the absence
of donor alloreactive T cells or GVHD. We observed similar results
with mice treated with ‘‘late’’ mDR5-1, indicating the continued sen-
sitivity of the thymus to TRAIL throughout the post-transplant pe-
riod, and that GVHD and/or conditioning-associated cytokines are
not required to enable TRAIL-mediated damage to the thymus.
Furthermore, we observed that on day 28 after T cell-depleted
allo-BMT, only 1-2% of donor thymocytes expressed DR5, suggest-
ing that mDR5-1 (and potentially TRAIL) mediate their effects on
thymic cellularity and function primarily via an indirect mechanism.
We conclude that the thymus is highly sensitive to GVHD and en-
dures severe damage at low levels of systemic GVHD. Furthermore,
we provide significant additional mechanistic insight into the tempo-
ral, cellular, and inflammatory requirements for TRAIL/DR5 medi-
ated damage to the thymus.408
P-SELECTIN REGULATES LEUKOCYTE TRAFFICKING AND EXPERIMEN-
TAL GRAFT-VERSUS-HOST-DISEASE AFTER ALLOGENEIC BONEMARROW
TRANSPLANTATION
Lu, S.X., Palomba, M.L., Na, I.-K., Terwey, T.H., Alpdogan, O.,
Bautista, J.L., Smith, M., Suh, D., King, C.G., Rao, U.K., Yim, N.,
Jenq, R.R., Zakrzewski, J.L., Holland, A.M., Penack, O., Dykstra, L.,
Bampoe, K., van den Brink, M.R.M. Memorial Sloan-Kettering Cancer
Center, New York, NY
P-selectin is found on most inflamed endothelium and interacts
with multiple leukocyte ligands. We found that P selectin-/- recipi-
ents of allogeneic bone marrow transplantation (allo-BMT) had sig-
nificantly less GVHD mortality and morbidity, as well as decreased
GVHD of the skin, liver and small bowels. This was associated with
diminished infiltration of alloactivated T cells into the Peyer’s
Patches and small bowels, coupled with increased numbers of donor
T cells in the spleen and secondary lymphoid organs (SLO) on day
14 and day 35 post-transplant. However, donor alloreactive T cells
in WT and P-selectin-/- allo-BMT recipients had similar alloactiva-
tion and apoptosis, and donor alloactivated T cells from WT and
P-selectin-/- allo-BMT recipients with GVHD showed similar pro-
liferation in vitro in a mixed leukocyte reaction, suggesting that the
inflammatory environment in WT and P-selectin-/- recipients was
comparable.
P-selectin glycoprotein ligand 1 (PSGL1) is the best-described
P-selectin ligand, and we then tested the role of PSGL1-/- donor al-
loreactive T cells in mediating GVHD. To our surprise, allo-BMT
recipients of WT and PSGL1-/- donor T cells had comparable sur-
vival and clinical GVHD scores, and further analyses on day 14 post-
transplant revealed similar numbers of donor alloactivated T cells in
the spleen, liver, mesenteric and peripheral lymph nodes, and Peyer’s
Patches. Additionally, WT and PSGL1-/- donor T cells had compa-
rable proliferation as measured by CFSE dilution, and comparable
alloactivation in vivo as determined by levels of CD25, CD44, and
CD62L.
We then asked whether PSGL1-/- T cells might display other P-se-
lectin ligands. Flow cytometric analyses of T cells from non-trans-
planted PSGL1-/- mice, and analyses of PSGL1-/- alloactivated T
